Abstracts tagged "Mortality"

Abstract Number: 1420 • ACR Convergence 2025
A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Isadora Small¹, Anuya Natu² and Augustine Manadan³, ¹The Latin School of Chicago, Chicago, IL, ²John H Stroger, Jr. Hospital of Cook County, Chicago, IL, ³Rush University Medical Center, Chicago, IL
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease with systemic complications that may contribute to increased mortality risk. This study examines the characteristics and…
Abstract Number: 0633 • ACR Convergence 2025
Diffuse Alveolar Hemorrhage in ANCA-Associated Vasculitis (AAV) and Systemic Lupus Erythematosus (SLE): A Comparative Analysis
Sai Shanmukha Sreeram Pannala¹, Medha Rajamanuri², Srikar Sama³, Fares Saliba⁴, Omar Mourad⁵, Elizabeth Fagin⁶, Koushik Varma Sangaraju⁷, Veena Katikineni⁸ and Anastasia Slobodnick⁹, ¹Northwell health/Staten Island university Hospital, new york city, NY, ²Southern Illinois University School of Medicine, Springfield, IL, ³University of California San Francisco Fresno, Fresno, CA, ⁴Staten Island University Hospital, Staten Island, NY, ⁵Zucker School of Medicine at Hofstra/Northwell at Staten Island University Hospital, Staten Island, NY, ⁶Staten Island University Hospital, Teaneck, NJ, ⁷St. Luke's University Health Network, Bethlehem, PA, ⁸Desert Orthopaedic and Rheumatologic Institute, Apple Valley, CA, ⁹Northwell, Staten Island, NY
Background/Purpose: Diffuse alveolar hemorrhage (DAH) is a rare but severe complication in Systemic Lupus Erythematosus (SLE), occurring in up to one-third of cases at disease…
Abstract Number: 0146 • ACR Convergence 2025
Association between frailty and delirium and hospitalization outcomes among older adults with rheumatic diseases
Bhavik Bansal¹, Yehseo Jung², Abdulla Damluji³, Parag Goyal⁴ and Namrata Singh⁵, ¹UT Southwestern Medical Centre, Dallas, TX, ²University of Washington, Seattle, WA, ³Johns Hopkins, Baltimore, ⁴Weill Cornell, New York, ⁵University of Washington, Bellevue, WA
Background/Purpose: We investigated the association of frailty and delirium, both independently and in combination, with in-hospital mortality and non-routine discharge (i.e. when a patient is…
Abstract Number: 2516 • ACR Convergence 2025
Mortality Trends in Primary Systemic Vasculitis in the United States (1999–2023)
Rameez Qasim¹, Sabah Mohib², Muhammad Ali³ and Khadija Mohib⁴, ¹Allama Iqbal Medical College Lahore, Lahore, Pakistan, ²N/A, Reseda, CA, ³Dow International Medical College, Karachi, Sindh, Pakistan, ⁴Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV
Background/Purpose: Primary systemic vasculitides comprise a group of immunological disorders that inflame blood vessel walls and are categorized by the size of the blood vessels…
Abstract Number: 1905 • ACR Convergence 2025
Exploring the Association Between Environmental Quality Index and Rheumatoid Arthritis Mortality in the United States
Rohan Sharma¹, Eric Yen² and Ram Singh³, ¹UCLA, Bakersfield, CA, ²UCLA, Los Angeles, CA, ³UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Environmental factors such as smoking, pollutants, diet, and geography as well as sex, race/ethnicity, and genetics have been linked with rheumatoid arthritis (RA) pathogenesis…
Abstract Number: 1397 • ACR Convergence 2025
Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.
Olga Rusinovich¹, Zulema Plaza², Monica Fernandez Castro³, Jose Rosas Gómez de Salazar⁴, Victor Martinez-Taboada⁵, Alex Olive⁶, Raúl Menor Almagro⁷, Belén Serrano-Benavente⁸, Judit Font-Urgelles⁹, Angel Garcia-Aparicio¹⁰, Sara Manrique-Arija¹¹, Jesús Alberto Garcia Vadillo¹², Ruth Lopez-Gonzalez¹³, Javier Narváez¹⁴, Maria Beatriz Rodriguez¹⁵, Carlos Galisteo¹⁶, Jorge Juan Gonzalez Martin¹⁷, Paloma Vela Casasempere¹⁸, Cristina Bohorquez¹⁹, MARIA CELIA ERAUSQUIN ARRUABARRENA²⁰, Beatriz Paredes-Romero²¹, Leyre Riancho-Zarrabeitia²², Sheila Melchor Diaz²³, José María Pego-Reigosa²⁴, Sergi Herdia²⁵, Clara Moriano²⁶, Mª Angeles Blazquez Cañamero²⁷, Paula Estrada-Alarcón²⁸, Enrique Judez²⁹, Nerea Alcorta-Lorenzo³⁰, Consuelo Ramos Giraldez³¹, Fernando Sánchez-Alonso³² and Jose Luis Andreu³³, ¹Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ³PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Solo practice, Barcelona, Spain, ⁷Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁸Hospital Gregorio Marañon, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Hospital Regional Universitario Málaga, Malaga, Spain, ¹²Hospital Universitario La Princesa, Madrid, Spain, ¹³Zamora Health Complex, Salamanca, Spain, ¹⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵Canarias University Hospital, La Laguna- Tenerife, Spain, ¹⁶Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁷HM Sanchinarro Univeristary Hospital, Madrid, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁹La Paz University Hospital, Alcalá De Henares, Spain, ²⁰Dr Negrin University Hospital, Ls Palmas, Spain, ²¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ²²Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²³¹² de Octubre University Hospital, Madrid, Spain, ²⁴Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²⁵Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁶Hospital León, LEON, Castilla y Leon, Spain, ²⁷Hospital Ramon y Cajal, Madrid, Spain, ²⁸Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, ²⁹Albacete University Hospital, Albacete, Spain, ³⁰Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: To evaluate the incidence of cardiovascular and cerebrovascular events (CVEs) in patients with Sjögren’s Disease (SjD), focusing on major adverse cardiovascular events (MACE), defined…
Abstract Number: 0627 • ACR Convergence 2025
Marked Decline in SLE Mortality Despite Rising Mortality in the General Population During the COVID-19 Pandemic
Omer Pamuk¹ and Ahmed Nasuhbeyoglu², ¹University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH
Background/Purpose: Previous studies have shown a decline in systemic lupus erythematosus (SLE)-related mortality rates from 1999 to 2020. This study aimed to evaluate SLE-related mortality…
Abstract Number: 0037 • ACR Convergence 2025
A Proteomic Signature Containing TNF Receptor Superfamily Member 10A (TNFRSF10A) and Growth/Differentiation Factor 15 (GDF-15) Improves Prediction of All-Cause Mortality Among Individuals with Gout, Beyond Atherosclerotic Cardiovascular and Other Clinical Risk Factors
Natalie McCormick¹, Sharan Rai², Chio Yokose³, Tony Merriman⁴, Robert Terkeltaub⁵ and Hyon K. Choi⁶, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital/Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Waltham, MA, ⁴University of Alabama at Birmingham, Homewood, AL, ⁵Retired, San Diego, CA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA
Background/Purpose: Gout affects >12 million US adults and is associated with premature all-cause and cardiovascular (CV) mortality which has failed to improve over recent decades,…
Abstract Number: 2504 • ACR Convergence 2025
Variables Associated with In-Hospital Mortality in Adult Eosinophilic Granulomatosis with Polyangiitis from the National Inpatient Sample Database 2017-2021
Anuya Natu¹, Isadora Small², Shilpa Arora³ and Augustine Manadan⁴, ¹John H Stroger, Jr. Hospital of Cook County, Chicago, IL, ²The Latin School of Chicago, Chicago, IL, ³Cook County Hospital, Chicago, IL, ⁴Rush University Medical Center, Chicago, IL
Background/Purpose: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a rare systemic vasculitis that can lead to significant morbidity and mortality. This study aims to evaluate the…
Abstract Number: 1897 • ACR Convergence 2025
Changes in SLE Mortality During and After the COVID-19 Pandemic
Laura Hernandez¹ and Ram Singh², ¹University of California, Los Angeles, Murrieta, CA, ²UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are vulnerable to infections due to both underlying immune dysfunction and the use of immunosuppressive therapies. Hence, it…
Abstract Number: 1392 • ACR Convergence 2025
Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers
Margaret Essien and Ram Singh, UCLA David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Sjögren's disease (SjD), an autoimmune condition with chronic inflammation in exocrine glands, is associated with increased risks of cancers. The impact of cancer on…
Abstract Number: 0597 • ACR Convergence 2025
Low 25-hydroxyvitamin D Levels are Associated with Higher Mortality and More Cardiovascular Events in Systemic Lupus Erythematosus
Theerada Assawasaksakul¹, Andrea Fava², Daniel Goldman³, Laurence Magder⁴ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, Baltimore, MD
Background/Purpose: No studies have directly examined the link between 25-hydroxyvitamin D [25(OH)D] and cardiovascular outcomes in SLE. This study aimed to assess this association, hypothesizing…
Abstract Number: 2492 • ACR Convergence 2025
Autoantibody Profiles and Disease Trajectories in Early Systemic Sclerosis: Insights from a Prospective Cohort
Marzieh Jamali¹, Amisha Kaur¹, Suiyuan Huang¹, James St. Clair², John Varga¹, Carleigh Zahn², Erica Mulcaire-Jones¹, Alain Lescoat¹ and Dinesh Khanna¹, ¹University of Michigan, Ann arbor, MI, ²University of Michigan, Ann Arbor
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease with high mortality. Early stratification by autoantibody (SSc-Ab) profile may inform prognosis and management, but data…
Abstract Number: 1882 • ACR Convergence 2025
Vessels Under Fire: National Mortality Trends in Systemic Vasculitides in the United States, 1999–2020
Aziz-ur-Rahman Khalid¹, Ghassan Makhoul², Hasan Munshi², Islam Rajab², Emmanuel Olumuyide³, MD Walid Akram Hussain², Ahmed Huzien² and Robert Lahita⁴, ¹St. Joseph's University Medical Center, wayne, ²St. Josephs University Medical Center, Paterson, ³Advocate Illinois Masonic Medical Center, Chicago, ⁴St. Josephs University Medical Center, Wayne, NJ
Background/Purpose: Systemic vasculitides are rare but potentially life-threatening inflammatory disorders affecting blood vessels. Despite therapeutic advances, national mortality trends across vasculitis subtypes remain poorly defined.…
Abstract Number: 1201 • ACR Convergence 2025
Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
Shiri Keret¹, Silvia Martinez Laverde², Irada Choudhuri², Raisa Lomanto Silva³, Eugenia Gkiaouraki², Tanya Chandra², Nantakarn Pongtarakulpanit⁴, Shreya Sriram², Niladri Bhowmick², Vaidehi Kothari², Kaushik Sreerama Reddy², Eaman Alhassan⁵, Anushka Aggarwal⁶, Maha Almackenzie⁷, Daniel Sullivan², Sara Faghihi-Kashani⁸, Koichi Yamaguchi², Daniel Kass², Kevin Gibson², Dana Ascherman⁹, Siamak Moghadam-Kia⁵, Chester V. Oddis⁹ and Rohit Aggarwal¹⁰, ¹Bnai Zion Medical Center, Atlit, Israel, ²University of Pittsburgh Medical Center, Pittsburgh, ³Massachusetts General Hospital, Boston, MA, ⁴Mahidol University, University of Pittsburgh, Bangkok, Thailand, ⁵University of Pittsburgh Medical Center, Pittsburgh, PA, ⁶Indraprastha Apollo Hospital, New Delhi, India, ⁷Medical Cities of the Ministry of the Interior, Riyadh, Saudi Arabia, ⁸UCSF, Mountain View, CA, ⁹University of Pittsburgh, Pittsburgh, PA, ¹⁰University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Lung involvement is the most frequent and severe extramuscular complication of Idiopathic Inflammatory Myopathy (IIM). The utility of pulmonary function test (PFT) monitoring for…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].